Condition: Acute Hypoxemic Respiratory Failure · Sponsor: Hospital del Mar Research Institute (IMIM)
The goal of this observational study is to determine whether metabolomic profiles combined with clinical data can predict high-flow nasal cannula (HFNC) failure and help optimize respiratory support in adult patients with acute hypoxemic respiratory failure (AHRF). The main questions it aims to answer are: Can metabolomic biomarkers identify patients at higher risk of HFNC failure? Does combining metabolomic and clinical data improve the prediction of respiratory support escalation and clinical outcomes? Participants will: Receive standard HFNC treatment according to clinical practice. Undergo collection of clinical, physiological, and laboratory data. Provide blood samples for metabolomic analysis during respiratory support.
This description comes directly from the study's public registry record.
Francisco José Parrilla-Gómez, MD, Phd · +34 747424848 · fparilla@hmar.cat
Joan Ramon Masclans Enviz, MD, PhD · +34 639383309 · jrmasclans@hmar.cat
Always discuss trial participation with your own doctor first.
| Hospital del Mar | Barcelona, Catalonia, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07607080